Dimethyl bisphenolate inhibits ovarian cancer growth by regulating the PI3K/AKT/mTOR signaling pathway

Area of Science:

• Oncology
• Pharmacology
• Natural Product Chemistry

Background:

• Ovarian cancer is a major gynecological malignancy with low survival rates.
• Current chemotherapy often leads to relapse and chemoresistance, necessitating novel treatments.
• Salvianolic acid B from Salvia miltiorrhiza Bge. is a key active compound.

Purpose of the Study:

• To evaluate the anti-ovarian cancer activity of a novel synthesized compound, Dimethyl bisphenolate (DMB).
• To elucidate the underlying mechanisms of DMB's anti-cancer effects.
• To assess the potential of DMB as a therapeutic candidate for ovarian cancer.

Main Methods:

• In vitro studies on ovarian cancer cell lines to assess proliferation and migration.
• Mechanistic investigations involving signaling pathways (PI3K/AKT/mTOR), energy metabolism, cell cycle, and apoptosis.
• In vivo efficacy assessment using a human ovarian cancer nude mouse xenograft model.

Main Results:

• DMB significantly inhibited ovarian cancer cell proliferation and migration in vitro.
• DMB suppressed tumor growth in vivo in a xenograft mouse model.
• Mechanisms include regulation of the PI3K/AKT/mTOR pathway, impaired energy metabolism, cell cycle arrest, and apoptosis induction.

Conclusions:

• Dimethyl bisphenolate (DMB) demonstrates potent anti-ovarian cancer activity both in vitro and in vivo.
• DMB exerts its effects by modulating key cellular pathways and inducing cell death.
• The scalable preparation and significant efficacy suggest DMB is a promising candidate for ovarian cancer therapy.